Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDH2 | P40926 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 12/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 12/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 12/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 10/20 | 0.39 |
| ▸ | CDK1 | P06493 | 10/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 10/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 10/20 | 0.39 |
| ▸ | GSK3A | P49840 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31622891 | 0.92 | CA12 (0.39) | KIF11 | |
| SCHEMBL31622890 | 0.92 | CA12 (0.39) | KIF11 | |
| SCHEMBL31291705 | 0.86 | MAPKAPK2 (0.41) | SLC6A4OPRM1OPRK1KIF11 | |
| SCHEMBL31291638 | 0.81 | SIGMAR1 (0.53) | MDH2GSK3BCDK5CDK5R1CCNB2 | |
| SCHEMBL31291768 | 0.81 | SIGMAR1 (0.53) | MDH2GSK3BCDK5CDK5R1CCNB2 | |
| SCHEMBL31291634 | 0.79 | SLC6A4 (0.50) | KDM4ETRPV1SLC6A4OPRM1OPRK1 | |
| SCHEMBL31291696 | 0.79 | FEN1 (0.35) | KDM4ESLC6A4OPRM1OPRK1KIF11 | |
| SCHEMBL31291729 | 0.75 | NCOA1 (0.43) | KDM4ESLC6A4OPRM1OPRK1 | |
| SCHEMBL31291737 | 0.71 | SLC6A4 (0.40) | SLC6A4 | |
| SCHEMBL15180316 | 0.69 | SIRT1 (0.38) | MDH2KDM4ESLC6A4OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376116-A1 | IBOGAINE AND NORIBOGAINE ANALOGS AND METHODS OF USE | DALRIADA DRUG DISCOVERY, INC. (CA) | 2024-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376116-A1 | IBOGAINE AND NORIBOGAINE ANALOGS AND METHODS OF USE | OPRM1, OPRD1, SIGMAR1 | MDH2 4389/4885GSK3B 766/4885CDK5 3944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.